Standard BioTools
LAB
99 hedge funds and large institutions have $223M invested in Standard BioTools in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 35 reducing their positions, and 38 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 35
0.04% less ownership
Funds ownership: 92.04% → 92% (-0.04%)
21% less funds holding
Funds holding: 125 → 99 (-26)
25% less capital invested
Capital invested by funds: $296M → $223M (-$73.1M)
68% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 38
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $80K
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMG
126
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$66K | -14,300 | Closed |
|
127
Jane Street
New York
| – | -$64K | -13,793 | Closed |
|
128
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$58K | -12,500 | Closed |
|
|
PP
129
Paloma Partners
Greenwich,
Connecticut
| – | -$55K | -11,972 | Closed |
|
130
Cerity Partners
New York
| – | -$50K | -10,721 | Closed |
|
131
Wolverine Trading
Chicago,
Illinois
| – | -$49K | -10,351 | Closed |
|
|
MPI
132
Mairs & Power Inc
St Paul,
Minnesota
| – | -$46K | -10,000 | Closed |
|
|
TRCT
133
Tower Research Capital (TRC)
New York
| – | -$29K | -6,135 | Closed |
|
|
PA
134
Parallel Advisors
San Francisco,
California
| – | -$8K | -1,727 | Closed |
|
|
PHK
135
Point72 Hong Kong
Hong Kong
| – | -$4K | -766 | Closed |
|
|
NIT
136
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$1K | -300 | Closed |
|
|
LTFS
137
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$222 | -63 | -88% |
|
LAB Hedge Fund Activity: Q4 2019 in Review
99 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2019, worth a combined $223M — down 25% from $296M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of LAB and 12 opened new positions — a net loss of 26 holders — while 35 trimmed existing stakes and 38 added.
The largest buyer was Russell Investments Group, adding an estimated $6.51M. The largest seller was RTW Investments, exiting entirely with an estimated $9.77M sold.
- 99 institutional investors held Standard BioTools (LAB) as of Q4 2019, down from 125 in Q3 2019.
- Funds reported $223M of Standard BioTools stock for Q4 2019, down 25% quarter-over-quarter.
- 12 funds opened new Standard BioTools positions in Q4 2019 and 38 closed out, a net change of -26 holders.
- The largest Standard BioTools buyer in Q4 2019 was Russell Investments Group, an estimated $6.51M added.
- The largest Standard BioTools seller in Q4 2019 was RTW Investments, an estimated $9.77M sold.
Based on aggregated 13F filings for Q4 2019.